Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Indivior : Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 02:01pm EDT
FILE PHOTO: Products produced by Reckitt Benckiser; Vanish, Finish, Dettol and Harpic are seen in London

(Reuters) - Reckitt Benckiser has agreed to pay up to $1.4 billion (£1.1 billion) to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment.

(Reuters) - Reckitt Benckiser has agreed to pay up to $1.4 billion (£1.1 billion) to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment.

The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film.

The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.

The indictment said Indivior also used an internet and telephone programme touted as a resource for opioid-addicted patients to connect them to doctors it knew were prescribing Suboxone and other opioids at high rates and in suspect circumstances.

The Justice Department said the scheme began before Indivior spun out of Reckitt in 2014 and resulted in thousands of opioid-addicted patients using the drug.

Opioids, including prescription painkillers and heroin, played a role in a record 47,600 U.S. overdose deaths in 2017, the U.S. Centers for Disease Control and Prevention has said.

Reckitt was not indicted like Indivior, but the department last year joined several whistleblower lawsuits alleging the British company improperly marketed the drug.

As part of Thursday's settlement, Reckitt entered into a non-prosecution agreement and agreed to pay nearly $1.35 billion to resolve the Justice Department's criminal and civil claims.

It will also pay $50 million to resolve FTC claims that it engaged in anticompetitive activities aimed at impeding competition from generic versions of Suboxone.

Reckitt said in a statement that it "acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct." But it said its board had decided the settlement was in the company's best interests.

Slough, England-based Indivior has pleaded not guilty to conspiracy and fraud charges. In a statement, it acknowledged Reckitt's settlement but said it had no new information on the case. Its trial in federal court in Abingdon, Virginia is set for May.


(GRAPHIC: Reckitt gains in value after Indivior spin-off -

'CLARIFIES LEGAL ENVIRONMENT'

Shares in Reckitt, whose products range from Mucinex cold medicine and Lysol cleaners, closed up 2.5%.

While the settlement is significantly higher than the $400 million that the consumer goods group had set aside to cover the cost of the investigations, analysts said it could allow the company's new chief executive to focus on a turnaround plan.

In an effort to regain investor confidence after setbacks including a safety scandal in South Korea, a failed product launch and a cyber attack, Reckitt's outgoing boss Rakesh Kapoor launched a plan to split the group into two business units – one for health and one for hygiene and home products.

Investors had feared the U.S. probes could hinder the transformation. Analysts at JP Morgan wrote in a note that settlement "clarifies the legal environment for RB and should allow the new management to focus on the RB 2.0 transformation."

While welcoming the settlement, AJ Bell investment director Russ Mould said the cost could limit incoming CEO Laxman Narasimhan's ability to undertake much-needed investment in Reckitt's brands.

"The danger is that Narasimhan will be operating with one hand tied behind his back," he said.

The company said it would increase its provision related to the investigations to $1.5 billion to cover both the cost of the settlement and "any remaining litigation exposures." It said the deal would be funded through existing borrowing facilities and cash generation.

Separately, Indivior also raised its full-year profit and revenue guidance after Suboxone lost market share at a slower pace than expected. Its shares closed 6.73% higher.

(Additional reporting by Siddharth Cavale in Bengaluru; Editing by Edmund Blair, Mark Potter and Susan Thomas)

By Noor Zainab Hussain, Pushkala Aripaka and Nate Raymond

Stocks mentioned in the article
ChangeLast1st jan.
INDIVIOR 2.71% 43.55 Delayed Quote.-60.84%
RECKITT BENCKISER 0.05% 6586 Delayed Quote.9.43%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INDIVIOR
07/15LONDON STOCK EXCHANGE : Chinese data, Antofagasta help FTSE 100 end longest losi..
RE
07/15INDIVIOR : U.S. Court Finds No Patent Violation in Rivals' Generic Medicine
DJ
07/12INDIVIOR : RB reaches settlement to fully resolve all federal investigations
AQ
07/12Reckitt Benckiser Is Fined $1.4 Billion In U.S. Opioids Case -- WSJ
DJ
07/12INDIVIOR : soars as generic copies fail to torpedo its market share
AQ
07/12INDIVIOR : Reckitt to cough up $1.4bn in US drug settlement
AQ
07/11Reckitt to Pay $1.4 Billion to Settle U.S. Opioid-Addiction Drug Probes -- 5t..
DJ
07/11INDIVIOR : Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment pr..
RE
07/11Reckitt to Pay $1.4 Billion to Settle U.S. Opioid-Addiction Drug Probes -- 4t..
DJ
07/11LONDON STOCK EXCHANGE : FTSE 100 drops as healthcare giants overshadow Fed-drive..
RE
More news
Financials (USD)
Sales 2019 716 M
EBIT 2019 145 M
Net income 2019 -
Finance 2019 381 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -8,13x
EV / Sales2019 0,03x
EV / Sales2020 0,40x
Capitalization 401 M
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 0,66  $
Last Close Price 0,55  $
Spread / Highest target 36,6%
Spread / Average Target 21,0%
Spread / Lowest Target -8,91%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
Ingo Elfering Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR-60.84%387
MERCK KGAA AG4.96%45 566
WUXI APPTEC CO LTD21.47%15 424
KYOWA HAKKO KIRIN CO LTD-9.23%9 168
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD18.62%8 909
JAZZ PHARMACEUTICALS PLC7.82%7 738